1.04  -0.2 (-16.13%)		01-16 16:00
Open: 1.13 High: 1.31 Volume: 448,520		Pre. Close: 1.24 Low: 1.03 Market Cap: 10(M)

Short term
Mid term
Targets	6-month :	1.32	1-year :	1.65
Resists	First :	1.13	Second :	1.41
Pivot price	0.89
Supports	First :	0.67	Second :	0.55
MAs	MA(5) :	1.01	MA(20) :	0.88
	MA(100) :	1.14	MA(250) :	1.47
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	63.5	D(3) :	60.8
RSI	RSI(14): 55.4
52-week	High :	4.11	Low :	0.67

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ GELS ] has closed below upper band by 22.5%. Bollinger Bands are 53.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	1.31 - 1.32	1.32 - 1.32
Low:	1.02 - 1.02	1.02 - 1.03
Close:	1.03 - 1.04	1.04 - 1.05

Gelteq Limited focuses on developing and commercializing a gel-based delivery system for humans and animals. It offers white label gel-based delivery solutions for prescription drugs, over-the-counter products, nutraceuticals and sports, pet care, and other products. The company was incorporated in 2017 and is headquartered in Caulfield, Australia.

Wed, 14 Jan 2026
GELS Stock Sees New Inflection Point Amid Market Volatility - timothysykes.com

Wed, 14 Jan 2026
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Benzinga

Tue, 13 Jan 2026
Gelteq Preclinical Results Show Increased Medicinal Cannabinoid Absorption - Cannabis Business Times

Thu, 11 Dec 2025
Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China - Stocktwits

Tue, 09 Dec 2025
Gelteq to Present at Investor Summit Virtual on December 9, 2025 - Stocktwits

Mon, 24 Nov 2025
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	0 (M)
Shares Float	11 (M)
Held by Insiders	5.46e+006 (%)
Held by Institutions	47.5 (%)
Shares Short	2 (K)
Shares Short P.Month	0 (K)

EPS	-3.84e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	969.4 %
Return on Equity (ttm)	-15 %
Qtrly Rev. Growth	413130 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-0.5 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-6 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	40610
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.